EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐chitinase‐3‐like 1 antibody attenuated atopic dermatitis‐like skin inflammation through inhibition of STAT3‐dependent CXCL8 expression

Ji Eun Yu iD, Seong Hee Jeon, Min Ji Kim, Dae Hwan Kim, Ja Keun Koo, Tae Hun Kim, Bongcheol Kim, Ji Yong Yoon, Young-Soo Lim, So Ra Park, In Jun Yeo iD, Jaesuk Yun iD und 4 weitere

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Ji Eun Yu und 15 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju-si, Chungbuk, Republic of Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, STAT3 Transcription Factor, Interleukin-8, Chitinase-3-Like Protein 1. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Chitinase‐3‐like 1 (CHI3L1) causes skin inflammation in the progression of atopic dermatitis. We investigated if anti‐CHI3L1 antibody could prevent the development of atopic dermatitis and its mechanisms of action. Experimental Approach The effect of CHI3L1 antibody on phthalic anhydride‐induced atopic dermatitis animal model and in vitro reconstructed human skin (RHS) model were investigated. Expression and release of atopic dermatitis‐related cytokines were determined using an enzyme‐linked immunosorbent assay, and RT‐qPCR, STAT3 and CXCL8 signalling were measured by western blotting. Key Results Anti‐CHI3L1 antibody suppressed phthalic anhydride‐induced epidermal thickening, clinical score, IgE level and infiltration of inflammatory cells, and reduced phthalic anhydride‐induced inflammatory cytokines concentration. In addition, CHI3L1 antibody treatment inhibited the expression of STAT3 activity in phthalic anhydride‐treated skin. It was also confirmed that CHI3L1 antibody treatment alleviated atopic dermatitis‐related inflammation in the RHS model. The inhibitory effects of CHI3L1 antibody was similar or more effective compared with that of the IL‐4 antibody. We further found that CHI3L1 is associated with CXCL8 by protein‐association network analysis. siRNA of CHI3L1 blocked the mRNA levels of CHI3L1, IL‐1β, IL‐4, CXCL8, TSLP, and the expression of CHI3L1 and p‐STAT, and the level of CXCL8, whereas recombinant level of CXCL8 was elevated. Moreover, siRNA of STAT3 reduced the mRNA level of these cytokines. CHI3L1 and p‐STAT3 expression correlated with the reduced CXCL8 level in the RHS in vitro model. Conclusion and Implications Our data demonstrated that CHI3L1 antibody could be a promising effective therapeutic drug for atopic dermatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicSTAT3 Transcription FactorInterleukin-8Chitinase-3-Like Protein 1HumansAnimalsSkinMaleMice, Inbred BALB CPhthalic AnhydridesAntibodiesMiceFemaleInflammation

Stichwörter der Autor:innen

CHI3L1CHI3L1 antibodyCXCL8STAT3atopic dermatitis

Substanzen

STAT3 Transcription FactorInterleukin-8Chitinase-3-Like Protein 1Phthalic AnhydridesAntibodiesphthalic anhydrideSTAT3 protein, human

Autor:innen und Institutionen

  • College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju-si, Chungbuk, Republic of Korea.
  • College of Pharmacy, Mokpo National University, Muan-gun, Jeonnam, Republic of Korea.
  • Autotelic Bio Inc., Cheongju-si, Chungbuk, Republic of Korea.
  • Senelix Co. Ltd., Songpa-gu, Seoul, Republic of Korea.
  • PRESTI GEBIOLOGICS Co. Ltd., Cheongju-si, Chungbuk, Republic of Korea.
  • New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do, Korea.

ORCID-Profile: Ji Eun Yu, In Jun Yeo, Jaesuk Yun, Jin Tae Hong

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Yu, J. E., Jeon, S. H., Kim, M. J., Kim, D. H., Koo, J. K., Kim, T. H., Kim, B., Yoon, J. Y., Lim, Y. S., Park, S. R., Yeo, I. J., Yun, J., Son, D. J., Han, S. B., Lee, Y. S., & Hong, J. T. (2024). Anti‐chitinase‐3‐like 1 antibody attenuated atopic dermatitis‐like skin inflammation through inhibition of STAT3‐dependent CXCL8 expression. British Journal of Pharmacology. https://doi.org/10.1111/bph.16365

Vancouver

Yu JE, Jeon SH, Kim MJ, Kim DH, Koo JK, Kim TH, et al. Anti‐chitinase‐3‐like 1 antibody attenuated atopic dermatitis‐like skin inflammation through inhibition of STAT3‐dependent CXCL8 expression. British Journal of Pharmacology. 2024. doi:10.1111/bph.16365

BibTeX
@article{Yu2024,
  author = {Yu, Ji Eun and Jeon, Seong Hee and Kim, Min Ji and Kim, Dae Hwan and Koo, Ja Keun and Kim, Tae Hun and Kim, Bongcheol and Yoon, Ji Yong and Lim, Young-Soo and Park, So Ra and Yeo, In Jun and Yun, Jaesuk and Son, Dong Ju and Han, Sang-Bae and Lee, Yong Sun and Hong, Jin Tae},
  title = {Anti‐chitinase‐3‐like 1 antibody attenuated atopic dermatitis‐like skin inflammation through inhibition of STAT3‐dependent CXCL8 expression},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16365}
}
Kostenlos starten →